申请人:Welfide Corporation
公开号:US06288061B1
公开(公告)日:2001-09-11
The present invention relates to the imidazole derivative of the following formula (I)
wherein R1 is hydrogen, optionally substituted alkyl and the like, R2 is hydrogen, optionally substituted alkyl and the like, R3is optionally substituted heteroaryl, R4 is optionally substituted cycloalkyl, optionally substituted phenyl and the like, provided that when R1 is hydrogen, and R2 and R4 are the same or different and each is phenyl or phenyl substituted by halogen atom, lower alkyl or lower alkoxy, R3 is benzothiazolyl or thiazolyl substituted by phenyl, the imidazole derivative of the following formula (XII)
wherein R6 is optionally substituted phenyl or optionally substituted heteroaryl and R7 is substituted phenyl, and pharmaceutically acceptable salts thereof. The compounds of the formulas (I) and (XII) and pharmaceutically acceptable salts thereof of the present invention inhibit IL-4 and IL-5 production by Th2 cells and are effective for the prophylaxis and treatment of allergic diseases such as atopic dermatitis, bronchial asthma, allergic rhinitis and the like.
本发明涉及下式(I)的咪唑衍生物,其中R1为氢、可选取代烷基等,R2为氢、可选取代烷基等,R3为可选取代杂环芳基,R4为可选取代环烷基、可选取代苯基等,但当R1为氢,且R2和R4相同或不同,且均为苯基或被卤素原子、低烷基或低烷氧基取代的苯基时,R3为苯并噻唑基或噻唑基,下式(XII)的咪唑衍生物,其中R6为可选取代苯基或可选取代杂环芳基,R7为取代的苯基,以及其药学上可接受的盐。本发明的式(I)和式(XII)化合物及其药学上可接受的盐能够抑制Th2细胞产生IL-4和IL-5,并且对于预防和治疗过敏性疾病,如特应性皮炎、支气管哮喘、过敏性鼻炎等具有有效性。